Study guide

5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans

ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring

1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal

2 Chapter 2: Assessment Foundations & Lifespan Considerations

2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)

3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation

3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles

4 Chapter 4: Cardiovascular Disorders

4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

5 Chapter 5: Respiratory Disorders

5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules

6 Chapter 6: HEENT & Allergic/Immunologic Disorders

6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency

7 Chapter 7: Endocrine & Metabolic Disorders

7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism

8 Chapter 8: Gastrointestinal & Hepatic Disorders

8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening

9 Chapter 9: Renal, Urological & Men's Health

9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

10 Chapter 10: Musculoskeletal & Rheumatologic Disorders

10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes

11 Chapter 11: Neurological & Psychiatric Disorders

11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care

12 Chapter 12: Dermatologic, Hematologic & Infectious Disease

12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies

13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care

13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions

14 Chapter 14: Gynecologic & Women's Health

14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)

15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination

15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment

16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement

16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics

5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans

Key Takeaways Explain This Topic AI

Asthma is a heterogeneous chronic inflammatory airway disorder characterized by variable expiratory airflow limitation, bronchial hyperresponsiveness, airway edema, and long-term airway remodeling.

Diagnostic confirmation requires spirometry demonstrating variable expiratory airflow limitation with significant bronchodilator reversibility (post-bronchodilator increase in FEV1 and/or FVC of ≥12% and ≥200 mL).

The Global Initiative for Asthma (GINA) establishes Track 1 (anti-inflammatory reliever / SMART with low-dose ICS-formoterol) as the preferred management paradigm across Steps 1 through 5 to dramatically reduce severe exacerbations and asthma-related mortality.

SABA-only monotherapy without concomitant Inhaled Corticosteroids (ICS) is strictly obsolete and no longer recommended due to adverse airway remodeling, receptor downregulation, and heightened risk of fatal exacerbations.

A written Asthma Action Plan (AAP) utilizes personal best Peak Expiratory Flow (PEF) and symptom thresholds to delineate Green (80–100%), Yellow (50–79%), and Red (<50%) zones, guiding immediate patient self-management and urgent clinical escalation.

Last updated: August 2026

Asthma: GINA Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans

Asthma is a complex, heterogeneous inflammatory disease of the conducting airways affecting over 25 million Americans. It is characterized by recurrent episodes of wheezing, breathlessness, chest tightness, and cough that vary over time and in intensity, paired with variable expiratory airflow limitation.

For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP) , board certification demands a thorough understanding of asthma endotypes and phenotypes, objective spirometric diagnostic criteria, the landmark Global Initiative for Asthma (GINA) Track 1 versus Track 2 stepwise therapeutic paradigms, written asthma action plans, and outpatient exacerbation management.

1. Pathophysiology, Endotypes & Airway Remodeling

Asthma is driven by chronic airway inflammation involving mast cells, eosinophils, T lymphocytes, neutrophils, and airway epithelial cells. Chronic inflammation leads to hyperresponsiveness of the tracheobronchial tree to various stimuli (allergens, viral infections, cold air, exercise, chemical irritants). +---------------------------------------------------------------------------------------------------+

  • | ASTHMA PATHOPHYSIOLOGICAL CASCADE |
  • | |
  • | [TRIGGERS / ALLERGENS] ---> Activates Dendritic & Airway Epithelial Cells |
  • | | |
  • | v |
  • | [CYTOKINE RELEASE] ---> IL-4, IL-5, IL-13 (T2-High) OR IL-17, IFN-gamma (T2-Low) |
  • | | |
  • | +--------------------------------+--------------------------------+ |
  • | | | |
  • | v v |
  • | [ACUTE RESPONSES] [CHRONIC AIRWAY REMODELING] |
  • | - IgE cross-linking on Mast Cells - Subepithelial collagen fibrosis |
  • | - Histamine, Leukotriene C4/D4/E4 release - Goblet cell metaplasia & mucus |
  • | - Acute smooth muscle bronchoconstriction - Smooth muscle hypertrophy |
  • | - Microvascular leakage & mucosal edema - Neo-angiogenesis |
  • | - Tenacious mucus plug formation - Fixed, irreversible obstruction |
  • +---------------------------------------------------------------------------------------------------+
  • Molecular Endotypes and Clinical Phenotypes

Modern asthma management classifies patients by underlying biological pathways to direct targeted therapy: +---------------------------------------------------------------------------------------------------+

  • | ASTHMA ENDOTYPES & PHENOTYPIC SPECTRUM |
  • | |
  • | 1. TYPE 2-HIGH (T2-HIGH) INFLAMMATION (~70% of Adult Asthma) |
  • | - Driven by T-helper 2 (Th2) cells and Type 2 Innate Lymphoid Cells (ILC2). |
  • | - Key Cytokines: IL-4 and IL-13 (drive IgE isotype switching and goblet cell hyperplasia); |
  • | IL-5 (drives eosinophil differentiation, maturation, and survival). |
  • | - Clinical Phenotypes: Early-onset allergic (atopic) asthma; Late-onset eosinophilic asthma; |
  • | Aspirin-Exacerbated Respiratory Disease (AERD). |
  • | - Biomarkers: Blood Eosinophils (>= 150-300 cells/mcL), Fractional Exhaled Nitric Oxide |
  • | (FeNO >= 25-50 ppb), Elevated Serum Total/Specific IgE. |
  • | - Therapeutic Response: Highly responsive to Inhaled Corticosteroids (ICS) and Biologics. |
  • | |
  • | 2. TYPE 2-LOW (T2-LOW / NON-T2) INFLAMMATION (~30% of Adult Asthma) |
  • | - Driven by Th1 and Th17 cells, neutrophil activation, or paucigranulocytic mechanisms. |
  • | - Key Cytokines: IL-8, IL-17, IL-22, Tumor Necrosis Factor-alpha (TNF-a). |
  • | - Clinical Phenotypes: Obesity-associated asthma; Smoking-related asthma; Late-onset non-atopic |
  • | asthma; Smooth muscle-predominant asthma. |
  • | - Biomarkers: Sputum neutrophils, Normal FeNO (<25 ppb), Normal blood eosinophils (<150/mcL). |
  • | - Therapeutic Response: Relatively corticosteroid-resistant; requires bronchodilator |
  • | optimization, LAMA add-on, weight reduction, and smoking cessation. |
  • +---------------------------------------------------------------------------------------------------+
  • 2. Objective Diagnostic Confirmation & Spirometric Criteria

Under GINA and NAEPP (National Asthma Education and Prevention Program) guidelines, a formal diagnosis of asthma requires two core elements :

A history of variable respiratory symptoms (wheeze, shortness of breath, chest tightness, cough).

Confirmed variable expiratory airflow limitation on objective pulmonary function testing. +---------------------------------------------------------------------------------------------------+

  • | SPIROMETRIC DIAGNOSTIC CRITERIA FOR ASTHMA |
  • | |
  • | 1. BASELINE AIRFLOW LIMITATION: |
  • | - Reduced FEV1 / FVC ratio: Normal is > 0.75 - 0.80 in adults; or < Lower Limit of Normal |
  • | (LLN based on age/sex/height z-scores). |
  • | |
  • | 2. POSITIVE BRONCHODILATOR REVERSIBILITY (BDR) TEST (GOLD STANDARD): |
  • | - Administer 4 puffs (400 mcg) of albuterol via MDI with spacer. |
  • | - Repeat spirometry 10-15 minutes later. |
  • | - POSITIVE CRITERIA: Increase in FEV1 and/or FVC of > 12% AND > 200 mL from baseline. |
  • | (Higher specificity if FEV1 increase > 15% and > 400 mL). |
  • | |
  • | 3. EXCESSIVE DIURNAL PEAK EXPIRATORY FLOW (PEF) VARIABILITY: |
  • | - Twice-daily PEF monitoring over 1-2 weeks. |
  • | - POSITIVE CRITERIA: Average daily diurnal PEF variability > 10% in adults: |
  • | Diurnal Variability = [(Day's Highest PEF - Day's Lowest PEF) / Day's Mean PEF] x 100% |
  • | |
  • | 4. BRONCHIAL PROVOCATION (BRONCHOPROVOCATION) TESTING: |
  • | - Indicated when spirometry is normal but asthma is strongly suspected clinically. |
  • | - Methacholine Challenge: Provocative Concentration causing a 20% drop in FEV1 |
  • | (PC20 <= 8 mg/mL indicates bronchial hyperresponsiveness; PC20 > 16 mg/mL rules out asthma)|
  • | - Exercise Challenge: Fall in FEV1 > 10% and > 200 mL after standardized exercise protocol. |
  • +---------------------------------------------------------------------------------------------------+
  • Comprehensive Diagnostic Differential & Clinical Mimics

Clinical Entity Distinguishing Clinical Features Diagnostic Findings vs. Asthma

Vocal Cord Dysfunction (VCD / ILO) Stridor localized to neck; sudden onset throat tightness; poor response to bronchodilators; common in young athletes, females, and healthcare workers. Normal spirometry or flattening of the inspiratory flow-volume loop (extrathoracic obstruction). Direct laryngoscopy during symptoms reveals paradoxical adduction of vocal cords on inspiration.

Chronic Obstructive Pulmonary Disease (COPD) Age >40; extensive tobacco history (>20 pack-years); chronic productive cough preceding dyspnea; slowly progressive. Post-bronchodilator FEV 1 / FVC < 0.70 \text{FEV}_1/\text{FVC} < 0.70 FEV 1 ​ / FVC < 0.70 (fixed ratio) that does not normalize; incomplete reversibility; reduced DLCO in emphysema.

Gastroesophageal Reflux Disease (GERD) Nocturnal dry cough, heartburn, sour water brash, globus sensation; symptoms worse postprandially or supine. Normal spirometry. Symptoms improve with trial of high-dose PPI and lifestyle modifications (elevate head of bed).

Congestive Heart Failure (Cardiac Asthma) Nocturnal dyspnea (PND), orthopnea, bilateral lower extremity pitting edema, S3 gallop, elevated jugular venous distention. Chest X-ray reveals cardiomegaly, pulmonary vascular congestion, and Kerley B lines; markedly elevated BNP / NT-proBNP; echocardiogram shows systolic or diastolic dysfunction.

Hypereosinophilic Syndromes / EGPA Severe refractory asthma, systemic vasculitis, peripheral neuropathy (mononeuritis multiplex), palpable purpura, sinusitis. Massive peripheral eosinophilia ( > 1 , 500 cells/ μ L >1,500\text{ cells/}\mu\text{L} > 1 , 500 cells/ μ L ), positive p-ANCA (anti-MPO) in 40–50%, pulmonary infiltrates on high-resolution chest CT.

3. GINA Stepwise Pharmacotherapy: The SMART Revolution

Historically, asthma guidelines recommended Short-Acting Beta-2 Agonists (SABA, e.g., albuterol) as standalone monotherapy for mild disease. However, milestone clinical trials (SYGMA 1 & 2, PRACTICAL, COMPASS) conclusively revealed that SABA monotherapy increases severe exacerbations and asthma-related mortality by leaving chronic mucosal inflammation untreated while inducing β 2 \beta_2 β 2 ​ -receptor downregulation, rebound bronchoconstriction, and eosinophilic airway infiltration.

GINA divides pharmacological management into two pathways: Track 1 (Preferred) and Track 2 (Alternative) . +---------------------------------------------------------------------------------------------------+

  • | GINA 2026 STEPWISE PHARMACOTHERAPY MATRIX |
  • | |
  • | ============================================================================================= |
  • | TRACK 1 (PREFERRED): RELIEVER IS LOW-DOSE ICS-FORMOTEROL (SMART / MART REGIMEN) |
  • | - Reduces severe exacerbations by 30-50% compared to SABA relievers. |
  • | - Whenever symptoms occur, the patient inhales a single dose of ICS + rapid-acting LABA. |
  • | --------------------------------------------------------------------------------------------- |
  • | STEP 1 & 2: As-needed low-dose ICS-formoterol ONLY (e.g., budesonide-formoterol 160/4.5 mcg |
  • | 1 puff PRN for symptoms; max 12 total puffs per day). |
  • | STEP 3: Low-dose ICS-formoterol MAINTENANCE (1 puff BID) PLUS as-needed low-dose |
  • | ICS-formoterol as RELIEVER (SMART regimen). |
  • | STEP 4: Medium-dose ICS-formoterol MAINTENANCE (2 puffs BID) PLUS as-needed low-dose |
  • | ICS-formoterol as RELIEVER. |
  • | STEP 5: Add-on Long-Acting Muscarinic Antagonist (LAMA, e.g., Tiotropium Respimat); |
  • | High-dose ICS-formoterol maintenance; Phenotypic Biologic Evaluation. |
  • | ============================================================================================= |
  • | TRACK 2 (ALTERNATIVE): RELIEVER IS AS-NEEDED SABA (ALBUTEROL) |
  • | - Requires strict daily maintenance adherence; higher risk of non-compliance and exacerbations. |
  • | --------------------------------------------------------------------------------------------- |
  • | STEP 1: Anti-inflammatory reliever (AIR): as-needed combination ICS-SABA (added at Step 1 |
  • | in GINA 2026), OR take low-dose ICS whenever SABA is used for symptom relief. |
  • | STEP 2: Daily low-dose Inhaled Corticosteroid (ICS) MAINTENANCE + As-needed SABA reliever. |
  • | STEP 3: Daily low-dose ICS-LABA combination MAINTENANCE + As-needed SABA reliever. |
  • | STEP 4: Daily medium- or high-dose ICS-LABA MAINTENANCE + As-needed SABA reliever. |
  • | STEP 5: Add-on LAMA; High-dose ICS-LABA; Phenotypic Biologic Evaluation. |
  • +---------------------------------------------------------------------------------------------------+

Important

Formoterol's Unique Pharmacology: Why is Formoterol the only LABA approved for Single Maintenance and Reliever Therapy (SMART)?

Unlike salmeterol (which has a slow onset of 15–30 minutes), formoterol combines rapid onset of bronchodilation (1–3 minutes, identical to albuterol) with a long duration of action (12 hours) . When combined with budesonide or mometasone in a single inhaler, every rescue puff simultaneously treats acute bronchospasm and delivers anti-inflammatory corticosteroid to halt the underlying inflammatory cascade.

Comprehensive Inhaled and Systemic Asthma Pharmacotherapy

Drug Class & Prototype Agents Mechanism of Action Dosage & Step Placement Adverse Effects & Black Box Warnings

Inhaled Corticosteroids (ICS) ; • Budesonide (Pulmicort); • Fluticasone Propionate (Flovent); • Fluticasone Furoate (Arnuity); • Beclomethasone (QVAR); • Mometasone (Asmanex) Binds to intracellular glucocorticoid receptors; downregulates inflammatory gene transcription; reduces eosinophils, mast cells, and mucosal edema. Low, Medium, High daily dosing: ; • Budesonide: Low 200–400 mcg; Med 400–800 mcg; High >800 mcg/day; • Fluticasone Prop: Low 100–250 mcg; Med 250–500 mcg; High >500 mcg/day Oral candidiasis (thrush) , dysphonia, reflex cough. Counseling pearl: Always rinse mouth with water and spit after inhalation; use spacer with MDI.; High systemic doses: Cataracts, glaucoma, osteopenia, bruising.

Long-Acting β 2 \beta_2 β 2 ​ -Agonists (LABA) ; • Formoterol (Rapid onset); • Salmeterol (Slow onset); • Vilanterol (Ultra-long 24 hr) Stimulates intracellular adenylate cyclase, increasing cAMP; causes bronchial smooth muscle relaxation for 12–24 hours. Combined with ICS across Steps 3–5 (e.g., Budesonide/formoterol [Symbicort], Fluticasone/salmeterol [Advair], Fluticasone/vilanterol [Breo]). Tachycardia, palpitations, tremor, hypokalemia, QTc prolongation.; BLACK BOX WARNING: Never use LABA as monotherapy without an ICS in asthma (increases risk of asthma death!).

Long-Acting Muscarinic Antagonists (LAMA) ; • Tiotropium Respimat (Spiriva) Competitively antagonizes M3 muscarinic acetylcholine receptors on airway smooth muscle; prevents vagal bronchoconstriction. 1.25 mcg or 2.5 mcg (2 inhalations once daily via Respimat soft mist inhaler). Step 5 add-on. Dry mouth, urinary retention, narrow-angle glaucoma exacerbation, pupillary dilation if sprayed in eyes.

Leukotriene Receptor Antagonists (LTRA) ; • Montelukast (Singulair); • Zafirlukast (Accolate) Selectively blocks cysteinyl leukotriene-1 (CysLT1) receptors; reduces leukotriene-induced smooth muscle contraction, vascular permeability, and mucus. Montelukast: 10 mg orally once daily in the evening. Alternative add-on in Steps 2–4; preferred in allergic rhinitis comorbidity and AERD. Headache, dyspepsia, elevated transaminases.; FDA BLACK BOX WARNING: Serious neuropsychiatric events (agitation, depression, sleep disturbances, suicidal ideation and behaviors).

5-Lipoxygenase Inhibitor ; • Zileuton (Zyflo CR) Inhibits 5-lipoxygenase enzyme, blocking conversion of arachidonic acid to all leukotrienes (LTB4, LTC4, LTD4, LTE4). 1,200 mg ER orally BID with meals. Used in severe AERD. Hepatotoxicity (monitor ALT/AST monthly x 3 mo, then q3m) ; CYP1A2 inhibition (increases theophylline, warfarin levels).

4. Biologic Targeted Therapies for Severe Refractory Asthma (Step 5)

Patients with persistent uncontrolled symptoms or frequent exacerbations despite Step 4–5 high-dose ICS-LABA therapy require phenotypic biomarker evaluation for monoclonal antibody (biologic) selection: +---------------------------------------------------------------------------------------------------+

  • | PHENOTYPIC BIOLOGIC SELECTION IN SEVERE ASTHMA |
  • | |
  • | [ASSESS BIOMARKERS: Blood Eosinophils, Serum Total IgE, FeNO, Allergic Sensitization] |
  • | | |
  • | +--------------------------+--------------------------+--------------------------+ |
  • | | | | | |
  • | v v v v |
  • | [ELEVATED IgE +] [BLOOD EOSINOPHILS] [FeNO >= 25 ppb OR] [T2-LOW / BROAD] |
  • | [PERENNIAL ALLERGEN] [ >= 150-300 cells/mcL] [EOS >= 150 cells/mcL] [NO BIOMARKERS] |
  • | | | | | |
  • | v v v v |
  • | OMALIZUMAB (Xolair) MEPOLIZUMAB (Nucala) DUPILUMAB (Dupixent) TEZEPELUMAB |
  • | - Anti-IgE Monoclonal - Anti-IL-5 (100 mg SQ q4w)- Anti-IL-4R-alpha subunit (Tezspire) |
  • | - Dosing based on weight BENRALIZUMAB (Fasenra) (Blocks IL-4 & IL-13) - Anti-TSLP |
  • | and baseline IgE level - Anti-IL-5R-alpha receptor- 200/300 mg SQ q2w - 210 mg SQ q4w |
  • | - SQ q2-4 weeks - 30 mg SQ q4w x 3, then q8w- Also treats Eczema, CRSwNP- Any phenotype|
  • +---------------------------------------------------------------------------------------------------+

Caution

Anaphylaxis Risk with Biologics: Omalizumab (Xolair) carries a Black Box Warning for severe life-threatening anaphylaxis (occurring up to 24–48 hours post-injection). All patients initiated on biologic therapy must be observed in the clinic for the first 3 injections and prescribed an autoinjectable epinephrine pen with comprehensive usage training.

5. Asthma Control Assessment & Written Asthma Action Plans (AAP)

Asthma control must be reassessed at every clinical encounter across two distinct domains: Symptom Control (over the past 4 weeks) and Future Risk of Adverse Outcomes .

The GINA 4-Week Symptom Control Assessment

Ask the patient the following 4 standardized questions regarding the preceding 4 weeks:

  • Daytime asthma symptoms more than twice a week ? (Yes / No)
  • Any nighttime awakening due to asthma? (Yes / No)
  • Reliever needed for symptoms more than twice a week ? (Yes / No)

Any activity limitation due to asthma? (Yes / No) +-----------------------------------------------------------------------------+

  • | GINA SYMPTOM CONTROL CLASSIFICATION |
  • | |
  • | * WELL-CONTROLLED: 0 of the above criteria (None = "Yes") |
  • | * PARTIALLY CONTROLLED: 1 to 2 of the above criteria |
  • | * UNCONTROLLED: 3 to 4 of the above criteria |
  • +-----------------------------------------------------------------------------+
  • Written Asthma Action Plan Architecture

Every patient with asthma must have an individualized, written Asthma Action Plan (AAP) based on symptom status and personal best Peak Expiratory Flow (PEF): +---------------------------------------------------------------------------------------------------+

  • | STANDARDIZED ASTHMA ACTION PLAN (AAP) |
  • | |
  • | [GREEN ZONE: 80% to 100% of Personal Best PEF] - DOING WELL (CONTROLLED) |
  • | - Symptoms: No cough, wheeze, or dyspnea; sleeping through the night; normal activity. |
  • | - Management: Continue baseline daily controller medications as prescribed. |
  • | |
  • | [YELLOW ZONE: 50% to 79% of Personal Best PEF] - CAUTION (LOSS OF CONTROL) |
  • | - Symptoms: Increased cough, mild wheeze, chest tightness, waking at night, reduced activity. |
  • | - Management: |
  • | * Track 1 (SMART): Inhale 1-2 puffs of low-dose ICS-formoterol immediately; repeat q2-4h PRN. |
  • | * Track 2 (SABA): Inhale 2-4 puffs of albuterol q20min up to 3 doses; temporarily double or |
  • | quadruple daily ICS controller dose for 1-2 weeks. |
  • | * If symptoms or PEF do not return to Green Zone within 48 hours: Initiate oral Prednisone. |
  • | |
  • | [RED ZONE: < 50% of Personal Best PEF] - MEDICAL EMERGENCY (SEVERE EXACERBATION) |
  • | - Symptoms: Severe breathlessness, speaking in words/phrases, ribs pulling in, reliever failing.|
  • | - Management: |
  • | * Inhale 4-6 puffs of reliever immediately. |
  • | * Take Oral Prednisone (40-50 mg orally immediately). |
  • | * Call 911 or proceed immediately to the Emergency Department if PEF remains <50% or if |
  • | experiencing severe respiratory distress! |
  • +---------------------------------------------------------------------------------------------------+
  • 6. Acute Asthma Exacerbations & Primary Care Urgent Management

When a patient presents to the primary care or urgent care clinic in an acute exacerbation, immediate severity stratification dictates pharmacotherapy and disposition. +---------------------------------------------------------------------------------------------------+

  • | ACUTE ASTHMA EXACERBATION SEVERITY STRATIFICATION |
  • | |
  • | FEATURE MILD / MODERATE SEVERE LIFE-THREATENING |
  • | --------------------------------------------------------------------------------------------- |
  • | SPEECH Sentences / Phrases Words only Unable to speak |
  • | ALERTNESS Calm / Mildly anxious Agitated / Distressed Lethargic / Confused|
  • | RESPIRATORY RATE Increased (16-25/min) Tachypneic (> 28-30/min) Exhaustion / Bradypnea|
  • | ACCESSORY MUSCLE USE None / Mild Prominent / Retractions Paradoxical Thoraco-|
  • | abdominal movement |
  • | PULSE RATE 100 - 120 bpm > 120 bpm Bradycardia / Arrest|
  • | OXYGEN SATURATION 90% - 95% on room air < 90% on room air Severe cyanosis |
  • | PEF (% PERSONAL BEST) > 50% <= 50% Unobtainable |
  • | AUSCULTATION Variable wheezing Loud, expiratory/inspir. "SILENT CHEST" |
  • +---------------------------------------------------------------------------------------------------+

Urgent Primary Care Pharmacotherapy Protocol:

Inhaled Bronchodilators: Administer Albuterol (SABA) 4–8 puffs via MDI with spacer (or 2.5–5 mg via jet nebulizer) combined with Ipratropium bromide (SAMA) 500 mcg nebulized every 20 minutes for 3 consecutive doses (1st hour) .

Systemic Corticosteroids (Mandatory in all moderate-to-severe flares):

Prednisone 40–50 mg orally daily for 5 to 7 days in adults.

Clinical Pearl: Short courses ( ≤ 7 \le 7 ≤ 7 days) do NOT require a tapering dose ; abrupt cessation after 5–7 days is safe, prevents hypothalamic-pituitary-adrenal (HPA) axis suppression, and minimizes steroid side effects (insomnia, hyperglycemia, psychosis).

Controlled Supplemental Oxygen: Titrate via nasal cannula to achieve target SpO 2 \text{SpO}_2 SpO 2 ​ 93–95% in adults (avoid hyperoxia).

Inpatient / ED Escalation Thresholds:

Administer IV Magnesium Sulfate (2 g IV infusion over 20 minutes) for severe refractory exacerbations ( P E F < 50 % PEF < 50\% PEF < 50% or SpO 2 < 92 % \text{SpO}_2 < 92\% SpO 2 ​ < 92% despite initial bronchodilators).

Transfer to Emergency Department / ICU via emergency medical services (EMS) if the patient demonstrates signs of impending respiratory failure: "Silent chest" (absence of wheezing due to zero airflow), normal or elevated PaCO 2 \text{PaCO}_2 PaCO 2 ​ ( > 42 mmHg >42\text{ mmHg} > 42 mmHg indicating respiratory muscle fatigue and hypoventilation), lethargy, or inability to maintain SpO 2 > 90 % \text{SpO}_2 > 90\% SpO 2 ​ > 90% .

  • 7. Special Populations & Clinical Pearls
  • A. Exercise-Induced Bronchoconstriction (EIB)

Transient airway narrowing triggered by hyperventilation of cold, dry air during vigorous exercise, with FEV 1 \text{FEV}_1 FEV 1 ​ drop > 10 % >10\% > 10% occurring 5–15 minutes post-exercise.

First-line Prevention: Inhale low-dose ICS-formoterol (1 puff) or SABA (2 puffs) 10–15 minutes prior to exercise. Maintain warm-up and cool-down routines.

B. Aspirin-Exacerbated Respiratory Disease (AERD / Samter's Triad)

Clinical Triad: Asthma + Chronic Rhinosinusitis with Recurrent Nasal Polyposis + Acute Severe Bronchospasm within 30–120 minutes of ingesting Aspirin or Non-Selective NSAIDs (ibuprofen, naproxen, ketorolac).

Pathophysiology: Dysregulated arachidonic acid metabolism with overproduction of cysteinyl leukotrienes and downregulation of protective prostaglandin E2 ( P G E 2 PGE_2 PG E 2 ​ ).

Management: Strict lifelong avoidance of all COX-1 inhibitors (acetaminophen ≤ 650 mg \le 650\text{ mg} ≤ 650 mg or selective COX-2 inhibitors like celecoxib are generally tolerated). First-line medical therapy: Montelukast / Zileuton and Dupilumab ; refer for specialized aspirin desensitization if antiplatelet therapy is required for CAD.

C. Asthma in Pregnancy

Rule of Thirds: One-third of women experience symptom improvement, one-third remain unchanged, and one-third experience clinical worsening during pregnancy.

Crucial Principle: Uncontrolled maternal asthma and fetal hypoxia pose far greater risks to the fetus (low birth weight, prematurity, preeclampsia) than any asthma medications.

Preferred Controller: Inhaled Budesonide has the most extensive human pregnancy safety registry data; continue all indicated ICS-LABA maintenance therapies throughout gestation and labor.